FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Gleave

Research Profile

Disorders

Prostatic Neoplasms

Chemicals & Drugs

Living Beings

Anatomy

Tumor Cell Line

Procedures

Physiology

Co-author Network

Publications

TOP 3
Masaki Shiota; Ario Takeuchi; Anousheh Zardan; Jenny Bazov; Eliana Beraldi; Jennifer L Bishop; Kim Chi; Thomas Cordonnier; Ladan Fazli; Martin Gleave; Ka Mun Nip; Amina Zoubeidi
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.
Hidetoshi Kuruma; Francois Lamoureux; Gerrit Los; Hiroaki Matsumoto; Masaki Shiota; Christian Thomas; Jennifer Bishop; David Briere; Andrea Fanjul; Martin Gleave; Amina Zoubeidi
A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo.
Joseph Ischia; Martin Gleave
Radical prostatectomy in high-risk prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Gleave (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Masaki Shiota; Ario Takeuchi; Anousheh Zardan; Jenny Bazov; Eliana Beraldi; Jennifer L Bishop; Kim Chi; Thomas Cordonnier; Ladan Fazli; Martin Gleave; Ka Mun Nip; Amina Zoubeidi
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.
Cancer research 2013;73(10):3109-19.
2013: Hidetoshi Kuruma; Francois Lamoureux; Gerrit Los; Hiroaki Matsumoto; Masaki Shiota; Christian Thomas; Jennifer Bishop; David Briere; Andrea Fanjul; Martin Gleave; Amina Zoubeidi
A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo.
Molecular cancer therapeutics 2013;12(5):567-76.
2013: Joseph Ischia; Martin Gleave
Radical prostatectomy in high-risk prostate cancer.
International journal of urology : official journal of the Japanese Urological Association 2013;20(3):290-300.
2013: Sarah Hawley; Javier Hernandez; Antonio Hurtado-coll; Kyle Kuchinsky; Raymond Lance; Janet Liew; Daniel W Lin; Jesse K McKenney; Rosario Mendez-Meza; Peter S Nelson; Lisa F Newcomb; Marlo Nicolas; Jeff Simko; Elizabeth Smith; Imelda Tenggara; Ian M Thompson; Dean Troyer; Lawrence D True; Xiaotun Zhang; Peter R Carroll; June M Chan; Janet E Cowan; Luis Crouch; Ladan Fazli; Ziding Feng; Michelle Ferrari; Martin Gleave; James D Brooks
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.
Advances in anatomic pathology 2013;20(1):39-44.
2012: Virginie Baylot; Ladan Fazli; Carmen Garrido; Sophie Giusiano; Martin Gleave; Maria Katsogiannou; Julie Acunzo; Claudia Andrieu; David Taieb; Palma Rocchi
Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(12):2244-56.
2012: Amina Zoubeidi; Martin Gleave
Small heat shock proteins in cancer therapy and prognosis.
The international journal of biochemistry & cell biology 2012;44(10):1646-56.
2012: David J Mulholland; Marcus Ruscetti; Linh M Tran; Martin Gleave; Jiaoti Huang; Naoko Kobayashi; Allen Zhi; Hong Wu
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.
Cancer research 2012;72(7):1878-89.
2012: Colin C Collins; Francesca Demichelis; Ladan Fazli; Martin Gleave; Peter W Gout; Anne Haegert; Martin Hirst; Antonio Hurtado-coll; Anna V Lapuk; Martin Lubin; Christopher A Maher; Marco Marra; Mark A Rubin; Stanislav V Volik; Yuwei Wang; Shawn Anderson; Robert H Bell; Himisha Beltran; Joseph R Bertino; Sonal Brahmbhatt; Hongwei Cheng; Arul M Chinnaiyan; Chunxiao Wu; Hui Xue; Yuzhuo Wang
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.
Molecular cancer therapeutics 2012;11(3):775-83.
2012: Jing Jiao; Devon Lawson; Yunfeng Li; Linh M Tran; Shunyou Wang; Owen N Witte; Donghui Chen; Ladan Fazli; Isla P Garraway; Martin Gleave; Andrew S Goldstein; Changyong Guo; Antreas Hindoyan; Baohui Zhang; Hong Wu
Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.
PloS one 2012;7(8):e42564.
2011: Fred Saad; Eric Winquist; Lori Wood; Scott Berry; Kim Chi; Piotr Czaykowski; Bernie Eigl; Martin Gleave; Sebastien J Hotte; Jean-Baptiste Lattouf; Som D Mukherjee; Scott North; Michael Pollak
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5765-73.
2011: V Baylot; S Garcia; C Garrido; S Giusiano; Martin Gleave; Juan L Iovanna; M Katsogiannou; J Acunzo; C Andrieu; D Taieb; Palma Rocchi
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Cell death & disease 2011;2():e221.
2010: Cara L Ferreira; Donald T T Yapp; Sarah Crisp; Brent W Sutherland; Sylvia S W Ng; Martin Gleave; Corinne Bensimon; Paul Jurek; Garry E Kiefer
Comparison of bifunctional chelates for (64)Cu antibody imaging.
European journal of nuclear medicine and molecular imaging 2010;37(11):2117-26.
2010: Amina Zoubeidi; Kim Chi; Martin Gleave
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1088-93.
2009: Martin Gleave; Laurence Klotz; Samir S Taneja
The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
Urologic oncology 2009;27(1):81-6.
2008: Dong Lin; Akira Watahiki; Jane Bayani; Fang Zhang; Lin Liu; Victor Ling; Marianne D Sadar; John English; Ladan Fazli; Alan So; Peter W Gout; Martin Gleave; Jeremy A Squire; Yu-Zhuo Wang
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.
Cancer research 2008;68(11):4352-9.
2007: Amina Zoubeidi; Anousheh Zardan; Eliana Beraldi; Ladan Fazli; Richard Sowery; Paul S Rennie; Colleen Nelson; Martin Gleave
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.
Cancer research 2007;67(21):10455-65.
2007: Chang Xu; Lynn F Graf; Ladan Fazli; Ilsa Coleman; Denise E Mauldin; Danbin Li; Peter S Nelson; Martin Gleave; Stephen R Plymate; Michael E Cox; Beverly J Torok-Storb; Beatrice S Knudsen
Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.
The Prostate 2007;67(15):1621-9.
2007: Meritxell Gironella; Mylène Seux; Min-Jue Xie; Carla Cano; Richard Tomasini; Julien Gommeaux; Stephane Garcia; Jonathan Nowak; Man Lung Yeung; Kuan-Teh Jeang; Amandine Chaix; Ladan Fazli; Yoshiharu Motoo; Qing Wang; Palma Rocchi; Antonio Russo; Martin Gleave; Jean-Charles Dagorn; Juan L Iovanna; Alice Carrier; Marie-Josèphe Pébusque; Nelson J Dusetti
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(41):16170-5.
2007: Alan So; Boris A Hadaschik; Richard D Sowery; Martin Gleave
The role of stress proteins in prostate cancer.
Current genomics 2007;8(4):252-61.
2007: J Erin Tillman; Jialing Yuan; Guangyu Gu; Ladan Fazli; Ritwik Ghosh; Alex S Flynt; Martin Gleave; Paul S Rennie; Susan Kasper
DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells.
Cancer research 2007;67(10):4630-7.
2007: Donald T T Yapp; Janet Woo; Aileen Kartono; Jonathan Sy; Thomas Oliver; Kirsten Skov; Cameron J Koch; Hans Adomat; Wieslawa H Dragowska; Ladan Fazli; Ladan Fadzli; Thomas J Ruth; Michael J Adam; David Green; Martin Gleave
Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.
BJU international 2007;99(5):1154-60.
2007: Nancy J Nesslinger; Robert A Sahota; Brad Stone; Kayli Johnson; Navraj Chima; Caitlin King; Devon Rasmussen; Darcy Bishop; Paul S Rennie; Martin Gleave; Paul Blood; Howard Pai; Charles Ludgate; Brad H Nelson
Standard treatments induce antigen-specific immune responses in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(5):1493-502.
2007: Masayuki Kamada; Alan So; Mototsugu Muramaki; Palma Rocchi; Eliana Beraldi; Martin Gleave
Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells.
Molecular cancer therapeutics 2007;6(1):299-308.
2006: Martin Gleave; J Qian; C Andreou; Peter Pommerville; J Chin; R Casey; Gary Steinhoff; N Fleshner; D Bostwick; L Thomas; Roger S Rittmaster
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
The Prostate 2006;66(15):1674-85.
2006: Palma Rocchi; Paul Jugpal; Alan So; Shannon Sinneman; Susan Ettinger; Ladan Fazli; Colleen Nelson; Martin Gleave
Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.
BJU international 2006;98(5):1082-9.
2006: Hideaki Miyake; Mototsugu Muramaki; Toshifumi Kurahashi; Kazuki Yamanaka; Isao Hara; Martin Gleave; Masato Fujisawa
Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
Urology 2006;68(3):609-14.
2006: Fred Saad; Antonio Finelli; George Dranitsaris; Larry Goldenberg; Scott Bagnell; Martin Gleave; Neil Fleshner
Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature.
The Canadian journal of urology 2006;13 Suppl 3():16-24.
2006: Neil Fleshner; George Dranitsaris; Antonio Finelli; John Tsihlias; David Bell; Martin Gleave
Surgical wait times for patients with urological cancers: a survey of Canadian surgeons.
The Canadian journal of urology 2006;13 Suppl 3():3-13.
2006: Xiaowei Xie; Andy Eberding; Candice Madera; Ladan Fazli; William Jia; Larry Goldenberg; Martin Gleave; Emma S Guns
Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
The Journal of urology 2006;175(5):1926-31.
2006: Matthew J Martin; Nataliya Melnyk; Michelle Pollard; Mary Bowden; Hon Sing Leong; Thomas J Podor; Martin Gleave; Poul H B Sorensen
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
Molecular and cellular biology 2006;26(5):1754-69.
2006: Mira R Ray; Latif A Wafa; Helen Cheng; Rob Snoek; Ladan Fazli; Martin Gleave; Paul S Rennie
Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.
International journal of cancer. Journal international du cancer 2006;118(5):1108-19.
2006: Duan Yu; C Scott; William W-G Jia; Arrigo De Benedetti; B Jill Williams; Ladan Fazli; Y Wen; Martin Gleave; C Nelson; Paul S Rennie
Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter.
Cancer gene therapy 2006;13(1):32-43.
2005: Alan So; Shannon Sinnemann; David Huntsman; Ladan Fazli; Martin Gleave
Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
Molecular cancer therapeutics 2005;4(12):1837-49.
2005: Palma Rocchi; Eliana Beraldi; Susan Ettinger; Ladan Fazli; Robert L Vessella; Colleen Nelson; Martin Gleave
Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Cancer research 2005;65(23):11083-93.
2005: Carolyn Cao; Eric T Shinohara; Hecheng Li; Kenneth J Niermann; Kwang Woon Kim; SEKHAR KONJETI; Martin Gleave; Michael Freeman; Bo Lu
Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.
International journal of radiation oncology, biology, physics 2005;63(4):1228-36.
2005: Martin Gleave; W Kevin Kelly
High-risk localized prostate cancer: a case for early chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(32):8186-91.
2005: Martin Gleave; Kim N Chi
Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.
Annals of the New York Academy of Sciences 2005;1058():1-15.
2005: Martin Gleave; Hideaki Miyake; Kim Chi
Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
Cancer chemotherapy and pharmacology 2005;56 Suppl 1():47-57.
2005: Hideaki Miyake; Kazuki Yamanaka; Mototsugu Muramaki; Toshifumi Kurahashi; Martin Gleave; Isao Hara
Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer.
Oncology reports 2005;14(5):1371-5.
2005: Pedro Ferreira; Maria José Oliveira; Eliana Beraldi; Ana Rita Mateus; Takashi Nakajima; Martin Gleave; Jun Yokota; Fátima Carneiro; David Huntsman; Raquel Seruca; Gianpaolo Suriano
Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro.
Experimental cell research 2005;310(1):99-104.
2005: Alan So; Palma Rocchi; Martin Gleave
Antisense oligonucleotide therapy in the management of bladder cancer.
Current opinion in urology 2005;15(5):320-7.
2005: Anthony W Tolcher; Kim Chi; John Kuhn; Martin Gleave; Amita Patnaik; Chris H Takimoto; Garry Schwartz; Ian M Thompson; Kristin Berg; Susan D'Aloisio; Nevin Murray; Stanley R Frankel; Elzbieta Izbicka; Eric K Rowinsky
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3854-61.
2005: Kazuki Yamanaka; Martin Gleave; Mototsugu Muramaki; Isao Hara; Hideaki Miyake
Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
Oncology reports 2005;13(5):885-90.
2005: Martin Gleave; Hideaki Miyake
Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
World journal of urology 2005;23(1):38-46.
2005: Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Mechanisms of the development of androgen independence in prostate cancer.
World journal of urology 2005;23(1):1-9.
2005: Hideaki Miyake; Isao Hara; Kazuki Yamanaka; Mototsugu Muramaki; Martin Gleave; Hiroshi Eto
Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential.
Oncology reports 2005;13(2):341-5.
2004: Kirsten Skov; Hans Adomat; Mary Bowden; Wieslawa H Dragowska; Martin Gleave; Cameron J Koch; Janet Woo; Donald T T Yapp
Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages.
Radiation research 2004;162(5):547-53.
2004: Palma Rocchi; Alan So; Satoko Kojima; Maxim Signaevsky; Eliana Beraldi; Ladan Fazli; Antonio Hurtado-coll; Kazuki Yamanaka; Martin Gleave
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
Cancer research 2004;64(18):6595-602.
2004: A I So; Mary Bowden; Martin Gleave
Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.
BJU international 2004;93(6):845-50.
2004: Clara Tan; Séverine Cruet-Hennequart; Armelle A Troussard; Ladan Fazli; Penny Costello; Kym Sutton; Jeff Wheeler; Martin Gleave; Jasbinder S Sanghera; Shoukat Dedhar
Regulation of tumor angiogenesis by integrin-linked kinase (ILK).
Cancer cell 2004;5(1):79-90.
2003: Martin Gleave; Burkhard Jansen
Clusterin and IGFBPs as antisense targets in prostate cancer.
Annals of the New York Academy of Sciences 2003;1002():95-104.
2003: Michael Pether; S Larry Goldenberg; Kapil Bhagirath; Martin Gleave
Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
The Canadian journal of urology 2003;10(2):1809-14.
2003: Martin Gleave; Colleen Nelson; Kim Chi
Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
Current drug targets 2003;4(3):209-21.
2002: Peter W Hochachka; Jim L Rupert; Larry Goldenberg; Martin Gleave; P Kozlowski
Going malignant: the hypoxia-cancer connection in the prostate.
BioEssays : news and reviews in molecular, cellular and developmental biology 2002;24(8):749-57.
2002: Martin Gleave; Hideake Miyake; Uwe Zangemeister-Wittke; Burkhard Jansen
Antisense therapy: current status in prostate cancer and other malignancies.
Cancer metastasis reviews 2002;21(1):79-92.
2002: Hideaki Miyake; Martin Gleave; Sadao Kamidono; Isao Hara
Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence.
Urology 2002;59(1):150-4.
2000: Laurence Klotz; J Heaton; Michael Jewett; J Chin; Neil Fleshner; Larry Goldenberg; Martin Gleave
A randomized phase 3 study of intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy.
The Journal of urology 2000;164(5):1573-8.
2000: L Klotz; Martin Gleave; S Larry Goldenberg
Neoadjuvant hormone therapy: the Canadian trials.
Molecular urology 2000;4(3):233-7;discussion 239.
1999: Martin Gleave; A Tolcher; Hideaki Miyake; Colleen Nelson; B Brown; Eliana Beraldi; J Goldie
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2891-8.
1998: Rob Snoek; Nicholas Bruchovsky; Susan Kasper; Robert J Matusik; Martin Gleave; N Sato; Nasrin R Mawji; Paul S Rennie
Differential transactivation by the androgen receptor in prostate cancer cells.
The Prostate 1998;36(4):256-63.
1998: Martin Gleave; Nicholas Bruchovsky; S Larry Goldenberg; Paul S Rennie
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
European urology 1998;34 Suppl 3():37-41.